Who is sponsoring NCT04177940?

NCT04177940 is sponsored by University of Alabama at Birmingham.

What condition does NCT04177940 study?

NCT04177940 studies Osteoporosis.

What drugs are being tested in NCT04177940?

Interventions: DMAB Discontinuation and Switching.

What is the status of NCT04177940?

NCT04177940 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2024-12-09 · How we verify

Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study

NCT04177940 PHASE4 ACTIVE_NOT_RECRUITING

Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose).

Details

Lead sponsor	University of Alabama at Birmingham
Phase	PHASE4
Status	ACTIVE_NOT_RECRUITING
Enrolment	45
Start date	Mon Aug 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Aug 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Osteoporosis

Interventions

DMAB Discontinuation and Switching

Countries

United States